{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-000644","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.168943+00:00","generated_at":"2026-06-20T20:11:26.372431+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Collegium provides 2023 guidance: rev $565-580M, adj EBITDA $355-370M, $100M buyback","bullets":["Product revenue net expected $565-580M for 2023, up from ~$460M in 2022.","Adjusted EBITDA $355-370M, growing >4x rate of adjusted operating expenses ($135-145M).","Board authorized $100M share repurchase program through December 31, 2023.","Xtampza ER gross-to-net expected 61-63% in 2023, down from >65% previously.","Federal Circuit upheld Belbuca patents, blocking Alvogen generic entry until 2032."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-000644","json":"https://secwatch.observer/filing/0001104659-23-000644.json","markdown":"https://secwatch.observer/filing/0001104659-23-000644.md","text":"https://secwatch.observer/filing/0001104659-23-000644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923000644/0001104659-23-000644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923000644/tm231443d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:11:26.372431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}